TSO3 Inc

TSO3 — Investor Presentation (November 2016)

22 slides from TSO3's investor presentation, November 2016

  1. Slide 1: Creating the Improved Standard in Healthcare Sterile Reprocessing

    TSX:TOS Creating the Improved Standard in Healthcare Sterile Reprocessing™ Corporate Presentation November 2016

  2. Slide 2: Important Cautions Regarding Forward Looking Statements and Other Disclosures

    Important Cautions Regarding Forward Looking Statements and Other Disclosures TSX:TOS The statements in this presentation and oral statements made by representatives of TSO3 Inc. (“Company”) relating to matters that are not historical facts (including, without limitation, those regarding the timing

  3. Slide 3: TSO3 - Our Vision

    TSO3 - Our Vision TSX:TOS To Create the Improved Standard in Healthcare Sterile Reprocessing™ 3

  4. Slide 4: Company Milestones

    Company Milestones TSX:TOS 2009 - 2014 2016  Reworked products  Record revenues  Introduced STERIZONE®  Record assembly capacity 1998: 125L+ and VP4 Sterilizers  USD$20.7M in cash at Sept. 30, 2016 1  Founded  Sterilizers sold and used in  Extended FDA Claims to include  HQ: Québec Canadian

  5. Slide 5: Purpose

    Purpose TSX:TOS A Sterile Device for Every Procedure 5

  6. Slide 6: Multiple Large Target Markets

    Multiple Large Target Markets TSX:TOS Existing Low-Temp Sterilizer Market Now Possible: Endoscopy/GI Market • Fastest growing sterilization segment (9%–10% CAGR1) • Expanded opportunity to terminally sterilize far more of the 55m+ annual procedures in US4 • Total equipment replacement value: $4.5 bi

  7. Slide 7: Growing Demand for MIS & Endoscopy Procedures

    Growing Demand for MIS & Endoscopy Procedures TSX:TOS Aging Recovery Bed Minimally Invasive Surgeries Population Time Reduction (MIS) & Endoscopies Aging Population Expected to Drive Growth in MIS Surgeries and Endoscopies2 >30 million MIS procedures annually in the U.S.1 85+  Effective 75-84  Fas

  8. Slide 8: The Science – Patents or Pending or Applied For

    The Science – 36 Patents or Pending or Applied For TSX:TOS 8

  9. Slide 9: STERIZONE VP4 Sterilizer

    STERIZONE® VP4 Sterilizer TSX:TOS FDA-Cleared - Dual Sterilant, Low Temperature Sterilization System –With Multi-Channeled Flexible Scope Claim Advantages Dynamic Sterilant Delivery System™ • Single cycle – easy to use, error free cycle selection Proprietary Technology automatically adjusts the ster

  10. Slide 10: Improving Existing LT Sterilization Practice

    Improving Existing LT Sterilization Practice TSX:TOS Old Technology TSO3 Technology • 20+ year-old core technology  Next generation industry technology • Single sterilant  Dual Sterilant • Fixed delivery  Dynamic Delivery • Operators must choose from several  Simple Single Cycle Operation, Capti

  11. Slide 11: GI Endoscopy Market

    GI Endoscopy Market TSX:TOS Greenfield opportunity for Terminal Sterilization – Displacing HLD Potential to terminally sterilize far more of the 55m+ annual endoscopies1 Almost 50% are colonoscopies – none of which are terminally sterilized today1 Endoscopic Procedures in Europe & U.S.1,2 (millions)

  12. Slide 12: Modernizing GI Endoscope Reprocessing

    Modernizing GI Endoscope Reprocessing TSX:TOS Old Technology TSO3 Technology • Typically high level disinfection  Sterilization not high level disinfection • A fundamentally inferior level of certainty  Far higher degree of certainty • Many contaminated scopes  The only FDA-cleared technology val

  13. Slide 13: The Problem: Endoscopes & Superbugs

    The Problem: Endoscopes & Superbugs TSX:TOS  SUPERBUG = Antimicrobial Resistant Bacteria  2 million+ Americans suffer from antibiotic- resistant bacteria annually – 23,000 die1  CRE is resistant to most available antibiotics - up to 50% of infected patients die2  CRE infections increasingly prev

  14. Slide 14: A Call For Action

    A Call For Action TSX:TOS “Despite reprocessing in accordance with US guidelines, viable microbes and biologic debris persisted in clinically used [GI] endoscopes, suggesting current reprocessing guidelines are not sufficient to ensure successful decontamination.” “Residual contamination was detecte

  15. Slide 15: The Solution: FDA Clearance of Endoscope Claims

    The Solution: FDA Clearance of Endoscope Claims TSX:TOS FDA has cleared the STERIZONE® VP4 An Industry First: Sterilizer for the sterilization of multi- channeled flexible endoscopes (with July 2016: FDA cleared expanded indications for four or fewer channels) having internal lumens of ≥ 1.45 mm in

  16. Slide 16: Commercialization

    Commercialization TSX:TOS  Getinge Infection Control - Exclusive global “The STERIZONE® VP4 Sterilizer distributor to STERIZONE® VP4 Sterilizer uniquely addresses an unmet global need for cost effective, high throughput  Global sales & service - over 3,000 associates in sterilization of complex me

  17. Slide 17: Q3 2016 Financial Highlights – USD

    Q3 2016 Financial Highlights – USD TSX:TOS Quarterly Revenues  30 STERIZONE® VP4 Sterilizers sold driving (US$ Millions) Q1 + Q2 + Q3: Sold total of record revenues of $3.5M in Q3 2016 80 STERIZONE® VP4 Sterilizers to Getinge  80 units and $9.6M first nine months $3.5M  Gross margin of 32%, which

  18. Slide 18: Key Stats (TSX: TOS)

    Key Stats (TSX: TOS) All Dollars in USD, unless noted otherwise TSX:TOS Stock Price (11/1/16) CAD$3.27 Market Cap CAD$301M Cash & ST Investments (mrq) $20.7M 52 Week High-Low CAD$1.42-$3.82 Enterprise Value CAD$273M Total Assets (mrq) $29.6M Avg. Daily Vol. (3 mo.) 0.2M Date Founded 1998 Total Debt

  19. Slide 19: TSO3 Key Takeaways

    TSO3 Key Takeaways TSX:TOS  Razor/Razorblade recurring revenue business model with proprietary captive consumables.  Industry changing technology that is selling now Global Distribution Partner  Dual sterilant  Dynamic Sterilant Delivery SystemTM  Addressing multi-billion $ market opportunities

  20. Slide 20: Contact Us

    Contact Us TSX:TOS Investor Relations TSO3 Inc. - Canada Liolios Group, Inc. 2505, avenue Dalton Ron Both, Senior Managing Director Tel (949) 574-3860 Québec, Québec TOS@liolios.com G1P 3S5 CANADA Renmark Financial Communications Inc. Tel (418) 651-0003 Barry Mire, Vice President info@tso3.com Tel (

  21. Slide 21: Appendix

    Appendix +,

  22. Slide 22: Regulatory Progression - Endoscopes

    Regulatory Progression - Endoscopes TSX:TOS FDA is considering an expansion of its sterilization requirements1,2 Body Reprocessing FDA Device Class Highest Contact Requirements Today Signaled Sterile Body Sterilization Critical Critical Margin Cavity of Safety Mucous High Level Semi-Critical Critica

TSO3 — Investor Presentation (November 2016) on 6ix